Selgian 40 kg, Film coated tablets

国: アイルランド

言語: 英語

ソース: HPRA (Health Products Regulatory Authority)

即購入

ダウンロード 製品の特徴 (SPC)
12-05-2023
ダウンロード DSU (DSU)
24-11-2023

有効成分:

Selegiline hydrochloride

から入手可能:

Ceva Santé Animale

ATCコード:

QN06A

INN(国際名):

Selegiline hydrochloride

投薬量:

16.74 mg/tablet

医薬品形態:

Film-coated tablet

処方タイプ:

POM: Prescription Only Medicine as defined in relevant national legislation

治療領域:

ANTIDEPRESSANTS

認証ステータス:

Authorised

承認日:

2002-11-22

製品の特徴

                                SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
SELGIAN
40 KG
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substance:
Selegiline (as hydrochloride)
16.74 mg
For a tablet of
1020.00 mg
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
White film-coated tablet with two cross-scored lines on one side
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In dogs:
-
Treatment of behavioural disorders of purely emotional origin:
depression, dysthymia,
anxiety.
-
In combination with behaviour therapy, treatment of disorders of
emotional origin found in
hypersensibility/hyperactivity, separation anxiety, deprivation
syndrome and generalised
phobia.
4.3
CONTRAINDICATIONS
Owing to its MAOI properties, selegiline may act on prolactin
secretion. For want of specific
studies, the product should not be administered to pregnant and
lactating bitches.
4.4
SPECIAL WARNINGS (FOR EACH TARGET SPECIES)
The use of a dosage less than the recommended dosage may result in
exacerbation of the
dog’s aggressiveness in case of latent hierarchy conflict. If no
clinical improvement is
observed after 2 months, it is useless to continue the treatment.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Emotional disorders can mask hierarchical conflicts. In dominant dogs
suffering from an
emotional
disorder,
the
alleviation
of
the
disorder
can
sometimes
reveal
a
latent
aggressiveness. In such cases, behavioural therapy must be instituted.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL
PRODUCT TO ANIMALS
In case of accidental ingestion, seek medical advice and show the
package insert or the label
to the physician.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
None reported to date.
4.7
USE DURING PREGNANCY, LACTATION OR LAY
Cf contra-indications.
4.8
INTERACTION WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF
INTERACTION
None reported to date.
4.9
AMOUNTS TO BE ADMINISTERED AND 
                                
                                完全なドキュメントを読む
                                
                            

この製品に関連するアラートを検索

ドキュメントの履歴を表示する